Last updated: October 23, 2026. The facts below reflect the Commons Health and Social Care Committee report and news coverage available at the time of writing. NHS access policies can change — always check the latest guidance with your GP or NHS provider.

Medical disclaimer — please read. This article is for general information only and is not medical advice. Weight-loss medicines such as Mounjaro (tirzepatide) are prescription-only drugs. Never start, stop or buy them — including from private online sellers — without a qualified doctor's assessment, especially if you are pregnant, breastfeeding, elderly, diabetic, or have heart, kidney, liver, pancreas or thyroid problems.

Mounjaro NHS 2026: MPs Slam 'Unambitious' Rollout — Who Qualifies, Side Effects & Safe Home Care

MPs have slammed the NHS rollout of the weight-loss injection Mounjaro as "unambitious", warning that only about 6% of eligible patients will receive it on the NHS in its first three years — while more than a million people in the UK are now paying for weight-loss injections privately. Here is what the Commons Health and Social Care Committee's October 2026 report actually says, who qualifies for Mounjaro (tirzepatide) on the NHS, what the known side effects are, and how home nursing support can help people managing long-term treatment safely.

Mounjaro NHS rollout: what the MPs' report says

• "Unambitious" and "woefully small": the cross-party Commons Health and Social Care Committee says just 6% of those eligible will get — or currently receive — Mounjaro in its first three years on the NHS, and urges the government to "urgently reassess the pace of rollout".
• 2.8 million people eligible: the NHS estimated that 2.8 million people would qualify for Mounjaro — but if all of them signed on in the first year, the cost would be £15.2 billion over five years, so NHS England asked for a gradual introduction instead: only 220,000 people over three years (by 2028).
• 2.4 million packs a month, mostly private: around 2.4 million packs of GLP-1 weight-loss drugs are prescribed every month in the UK — but the vast majority are bought privately. More than a million people are estimated to be paying for weight-loss injections themselves, including Mounjaro and Wegovy.
• A "two-tier system": committee chair Layla Moran said weight-loss drugs "remain out of reach for those who can't afford them", warning that limited NHS supply has "inadvertently deepen[ed] health inequalities". The committee notes obesity costs the UK economy around £75 billion a year.
• Treat obesity like diabetes: MPs want obesity treated as a long-term, managed condition like diabetes, and call for a government summit on GLP-1 access with providers and healthcare professionals, plus better use of digital providers to speed up the rollout.

The NHS said it is "testing new ways to accelerate access, including new routes for starting these medicines". The 12-year rollout plan for Mounjaro is under review. (Sources: BBC News via worldrightnowlive.com; Radio X; britbrief.co.uk — all October 22–23, 2026.)

What is Mounjaro? How the weekly weight-loss injection works

Mounjaro (generic name: tirzepatide) is one of the best-known GLP-1 drugs, alongside Wegovy (semaglutide) and Ozempic. It is taken as a once-weekly injection. It works by mimicking gut hormones that suppress appetite and make a person feel fuller for longer, which — combined with a reduced-calorie diet and increased physical activity — leads to significant weight loss for many patients.

In June 2024, the National Institute for Health and Care Excellence (Nice) recommended Mounjaro as an option for managing overweight and obesity. Wegovy has also been approved by the NHS, but is currently available only through specialist weight management services.

Who qualifies for Mounjaro on the NHS? Eligibility explained

NHS access is currently narrow — that is exactly what MPs are complaining about. In broad terms, NICE's criteria for tirzepatide on the NHS are based on body-mass index (BMI) plus weight-related health problems, and referral to (or assessment by) specialist weight management services. Lower BMI thresholds apply for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. Treatment is meant to continue only if it is working — typically a target of at least 5% weight loss within six months.

Mounjaro side effects: what is known so far

Like all prescription medicines, Mounjaro can cause side effects. The most commonly reported are digestive: nausea, vomiting, diarrhoea or constipation, and reduced appetite — usually worst when starting or when the dose is increased, and often settling over time. Injection-site redness or discomfort is also reported.

More serious risks discussed in medical guidance and the product information include inflammation of the pancreas (pancreatitis), gallbladder problems, kidney problems from dehydration caused by vomiting or diarrhoea, and allergic reactions. The label also carries a boxed warning about thyroid C-cell tumours seen in animal studies — Mounjaro is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Certain groups need extra caution: people with diabetes on insulin or sulfonylureas (risk of low blood sugar), people with a history of pancreatitis or gallbladder disease, and anyone pregnant, planning pregnancy or breastfeeding. Again — this is exactly the kind of risk assessment a doctor must do before prescribing. If you take a GLP-1 drug and develop severe stomach pain, persistent vomiting, or signs of an allergic reaction, seek medical care promptly.

Using weekly weight-loss injections safely at home

Because Mounjaro is a once-weekly injection that many patients will use for a year or longer, safe day-to-day management matters as much as the prescription itself:

• Storage: keep the pens refrigerated as the leaflet directs; never use a pen past its expiry date.
• Routine: inject on the same day each week; rotate the injection site (abdomen, thigh or upper arm) and never share a pen.
• Missed dose: follow the leaflet's guidance (usually: take it as soon as remembered within a few days, otherwise skip to the next weekly dose) — do not double up.
• Hydration and nutrition: eat smaller, protein-rich meals, avoid fatty foods that worsen nausea, and drink plenty of water — vomiting and diarrhoea can dehydrate you quickly.
• Tracking: keep a simple log of injection dates, side effects, weight and blood pressure, and bring it to follow-up appointments.

How home nursing can support people on long-term treatment

For elderly patients, people with chronic illnesses, or anyone who struggles with a strict weekly routine, a trained home nurse or caregiver can make long-term treatment safer and easier to stick with: reminding and supporting the weekly injection schedule under the prescribing doctor's guidance, monitoring blood pressure and blood sugar, watching for side effects like nausea or dehydration, helping with meal planning and mobility, and keeping the treatment log the doctor needs at reviews.

Fatima Home Nursing Care provides certified nurses, caregivers and physiotherapists for home-based care in Karachi, Lahore, Islamabad and Hyderabad — and our overseas Pakistanis service keeps families abroad updated on their parents' care in their own timezone. If a loved one is starting long-term treatment, WhatsApp us on +92 308 3688218 to discuss a care plan.